Zhonghe Gene

Cover Block

PUBLIC

Attribute	Detail
Name	Zhonghe Gene
Tagline	Enzymatic DNA synthesis equipment and services for synthetic biology
Headquarters	Tianjin, China
Founded	2022
Stage	Seed
Business Model	B2B
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	East Asia
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://zhonghegene.com
• LinkedIn: https://www.linkedin.com/company/tianjin-zhonghe-gene-technology

Executive Summary

PUBLIC

Zhonghe Gene is a Chinese deeptech startup commercializing enzymatic DNA synthesis equipment, a capital-intensive niche where technical execution and intellectual property define the competitive moat. Founded in 2022, the company is developing the TIESyno®-96 DNA biosynthesizer and related reagents, positioning itself within the shift toward more sustainable, enzyme-based DNA manufacturing for synthetic biology and biomedical research [Preqin, Jan 2026]. The founding story is anchored in academic research, with sole founder Huifeng Jiang serving as a researcher at the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, suggesting the venture likely emerged from institutional IP [Preqin].

Its primary differentiation rests on the development of integrated hardware and consumables for enzymatic synthesis, an alternative to the traditional phosphoramidite chemistry used by established players. The business model appears to follow a capital equipment and reagents sales approach, though specific pricing and customer traction are not publicly detailed. Funding has come from seed rounds in 2024 and early 2026, with investors including the Changzhou Municipal Government Investment Fund Management, Apricot Capital, and Lenovo, signaling support from both venture capital and strategic, government-aligned entities [Crunchbase, Feb 2024] [Preqin, Jan 2026].

Over the next 12-18 months, the key monitorables are the commercial launch and customer adoption of its flagship synthesizer, any disclosed partnerships with research institutes or biopharma companies, and subsequent funding rounds that would validate its technical roadmap and scaling plans.

Data Accuracy: YELLOW -- Core company description and funding investors are documented by Preqin and Crunchbase; founder background and product details are from a single source.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	Biotech / Life Sciences
Geography	East Asia
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Undisclosed

Company Overview

PUBLIC

Zhonghe Gene emerged in 2022 from a research base in Tianjin, China, with a focus on shifting DNA synthesis from chemical to enzymatic methods. The company’s founding is anchored to its sole named founder, Huifeng Jiang, who is identified as a researcher at the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences [Preqin, Jan 2026]. This academic origin suggests the venture’s initial intellectual property and technical roadmap were likely developed within a state-affiliated research institute, a common pathway for deeptech startups in the region.

The company’s headquarters and primary operations remain in Tianjin, with a significant expansion milestone occurring in early 2024. According to a local government announcement, Zhonghe Gene was set to launch a DNA synthesis equipment project in Changzhou, indicating a strategic move to establish manufacturing or R&D presence in another major industrial hub [Changzhou Government, Apr 2024]. This was followed by a venture funding round in January 2026 led by the Changzhou Municipal Government Investment Fund Management, formally tying the company’s growth to municipal investment and industrial policy in Jiangsu province [Preqin, Jan 2026].

A separate seed round was recorded in February 2024, though the lead investor and amount were not disclosed [Crunchbase, Feb 2024]. The investor syndicate, as pieced together from various profiles, includes Apricot Capital, Beiyang Haitang Fund, and Lenovo, alongside the government fund [Tracxn] [CB Insights]. The sequence of funding and the geographic expansion to Changzhou represent the key verifiable milestones for the firm to date.

Data Accuracy: YELLOW - Core founding and funding facts are confirmed by Crunchbase and Preqin, but some investor details are aggregated from unverified platform profiles.

Product and Technology

MIXED The company's core offering centers on a proprietary instrument for enzymatic DNA synthesis, a technology that aims to displace traditional chemical methods with a more sustainable and potentially scalable biological process. According to its profile, Zhonghe Gene develops and manufactures the TIESyno®-96 DNA biosynthesizer, a gene splicer, and related DNA biosynthesis reagents and consumables [Preqin, Jan 2026]. The product suite is positioned to serve applications in DNA research, synthetic biology, and biomedicine, with the company also offering bio-based gene synthesis services.

While detailed technical specifications for the TIESyno®-96 are not publicly available, the instrument's name suggests a 96-well plate format, a common standard for laboratory automation that would enable parallel synthesis. The focus on a full-stack solution,hardware, reagents, and services,indicates a strategy to capture value across the DNA synthesis workflow, rather than selling enzymes or consumables alone. Public materials do not disclose throughput, error rates, or maximum oligo length, which are critical benchmarks for evaluating synthesis platforms against incumbents.

PUBLIC

The market for synthetic biology tools is expanding beyond foundational research into industrial and therapeutic applications, creating a pull for more efficient and scalable DNA production methods. For a company like Zhonghe Gene, the commercial opportunity is tied directly to the pace of adoption in these downstream fields.

Third-party estimates for the total addressable market (TAM) for enzymatic DNA synthesis are not publicly available in the cited research. As an analogous market, the broader DNA synthesis market was valued at approximately $4.7 billion in 2023 and is projected to reach $13.2 billion by 2030, according to a report from Grand View Research [Grand View Research, 2024]. This growth is often linked to demand from synthetic biology, which itself is forecast to be a $45 billion market by 2028 [McKinsey, 2022]. While these figures encompass a wide range of technologies and services, they illustrate the scale of the end-markets that Zhonghe Gene's equipment aims to serve.

Demand drivers for next-generation synthesis equipment are well-documented. The primary tailwind is the shift in synthetic biology from proof-of-concept research to scaled production, which requires longer, more accurate, and more cost-effective DNA constructs. This is particularly relevant for applications in therapeutic antibody development, engineered cell therapies, and industrial enzyme production. A secondary driver is the push for greener manufacturing processes. Traditional phosphoramidite-based DNA synthesis relies on hazardous chemicals, creating regulatory and environmental pressure that favors enzymatic methods, which use water-based reactions [Nature Reviews Bioengineering, 2023].

Key adjacent markets that could influence demand include DNA data storage and CRISPR-based gene editing. While still largely in the research phase, DNA data storage represents a potential long-term source of massive, repetitive synthesis demand. The gene editing market, valued in the tens of billions, relies on high-quality synthetic DNA for guide RNAs and repair templates, creating a direct and growing consumables market for synthesis providers [CB Insights, 2024].

Regulatory and macro forces present a mixed picture. In China, synthetic biology is a named priority in national five-year plans, often translating into direct funding and policy support for domestic equipment manufacturers like Zhonghe Gene [Changzhou Government, Apr 2024]. However, geopolitical tensions and export controls on advanced biotech equipment could simultaneously create a protected domestic market while limiting international expansion opportunities. The regulatory pathway for equipment is generally less burdensome than for therapeutics, but end-use in clinical applications may still attract scrutiny.

Therapeutic Antibodies | 35 | %
Industrial Enzymes | 25 | %
Basic Research | 20 | %
Gene & Cell Therapy | 15 | %
Other | 5 | %

The chart above estimates the breakdown of current demand drivers for long, high-fidelity DNA synthesis, based on analyst surveys of the synthetic biology service provider landscape [SynBioBeta, 2025]. The heavy weighting toward therapeutic and industrial applications underscores the commercial shift from research tools to production-scale inputs.

Data Accuracy: YELLOW -- Market sizing relies on analogous, broader industry reports. The demand driver segmentation is based on a single trade survey.

Competitive Landscape

MIXED Zhonghe Gene operates in a specialized segment of synthetic biology, where the competitive map is defined by the underlying DNA synthesis technology and the commercial model for delivering it.

The company's primary competition comes from other firms developing enzymatic DNA synthesis (EDS) platforms, which are positioned as a next-generation alternative to the traditional, chemical-based phosphoramidite method. The competitive field is currently small, with a handful of well-funded private companies and one established public player offering a broader suite of services.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Zhonghe Gene	Developer of enzymatic DNA synthesis (EDS) equipment (TIESyno-96) and reagents for synthetic biology research.	Seed stage; undisclosed rounds in 2024 and 2026 from Chinese government and venture funds.	Focus on integrated hardware (biosynthesizer) and reagent system; early-stage academic founder with ties to national synthetic biology research center.	[Preqin, Jan 2026]
Ansa Biotechnologies	Developer of a fully enzymatic DNA synthesis platform, offering synthesis-as-a-service.	Venture-backed; raised $68M Series A in 2022.	Pioneering a proprietary, fully enzymatic synthesis process; commercial model is service-based rather than equipment sales.	[Crunchbase]
DNA Script	Developer of benchtop enzymatic DNA printers (SYNTAX system) for on-demand, rapid DNA synthesis.	Late-stage private; raised over $200M from investors like Casdin Capital, Merck KGaA.	Commercialized desktop instrument for in-lab synthesis; strong IP portfolio and partnerships with large pharma and government agencies (e.g., IARPA).	[Crunchbase]
Twist Bioscience	Public provider of synthetic DNA, next-generation sequencing, and biopharma discovery services using silicon-based manufacturing.	Public (NASDAQ: TWST); market cap ~$2.2B (April 2025).	Scale and cost advantages from silicon wafer-based chemical synthesis; extensive product catalog and established customer base across academia and industry.	[Twist Bioscience]

Incumbency in this field is currently held by Twist Bioscience, which has scaled a high-throughput, chemical synthesis process. Its competitive advantage is rooted in manufacturing scale, a vast catalog of gene fragments, and an entrenched position in research pipelines. For customers prioritizing cost-per-base-pair and volume over synthesis speed or sustainability, Twist remains the default. The challengers, including Zhonghe Gene, Ansa Biotechnologies, and DNA Script, are betting that the benefits of enzymatic synthesis,potentially longer strand lengths, faster turnaround, and a more sustainable chemical process,will justify a shift in the market.

Zhonghe Gene's defensible edge today appears to be its focus on the integrated hardware system and its roots in China's state-backed research ecosystem. Founder Huifeng Jiang's affiliation with the Tianjin Institute of Industrial Biotechnology and the National Center of Technology Innovation for Synthetic Biology suggests potential access to foundational IP and collaborative research projects [Preqin]. The participation of the Changzhou Municipal Government Investment Fund Management as an investor signals alignment with regional industrial policy, which could facilitate early adoption in local academic and biomanufacturing hubs [Preqin, Jan 2026]. This edge is durable if it translates into preferential procurement or subsidized pilot programs, but it is perishable if it fails to expand beyond a regional footprint or if global competitors establish similar in-country partnerships.

The company's most significant exposure is its late entry and limited commercial visibility compared to capitalized peers. DNA Script has a multi-year head start in commercializing a desktop enzymatic printer and has secured strategic partnerships. Ansa Biotechnologies, while also a service provider, has secured substantial venture capital to refine its core enzymatic chemistry. Zhonghe Gene has not publicly disclosed instrument sales, service contracts, or named research collaborators, leaving its technical performance and customer acceptance unverified. Furthermore, its business model of selling synthesis equipment places it in direct competition with DNA Script's instrument strategy, requiring it to convince labs to adopt a new, unproven platform.

The most plausible 18-month competitive scenario involves further market segmentation. If enzymatic synthesis proves commercially viable for specific, high-value applications like long gene assembly or on-demand variant libraries, the winner will be the company that secures a flagship partnership with a major pharmaceutical or biomanufacturing entity. DNA Script is best positioned for this outcome given its existing pharma collaborations. Conversely, if the market decides that synthesis-as-a-service is the more capital-efficient path for most labs, the loser would be any pure hardware play that fails to gain instrument traction. In that case, Ansa's service model or Twist's scaled service offering would capture demand, while Zhonghe Gene would need to pivot toward a service arm or seek a niche in specialized research consortia within its supportive regional network.

Data Accuracy: YELLOW -- Competitor profiles and funding are confirmed by public databases; Zhonghe Gene's differentiation and competitive position are inferred from company descriptions and founder background.

Opportunity

PUBLIC The scale of the prize for Zhonghe Gene is the potential to become a foundational hardware and reagent supplier for a global synthetic biology industry moving beyond traditional, chemically intensive DNA synthesis.

The headline opportunity is to establish a standard laboratory instrument for enzymatic DNA synthesis, positioning the TIESyno®-96 as a default workhorse for academic and industrial labs in China and, eventually, abroad. This outcome is reachable not as a distant aspiration but as a logical extension of current trends. The synthetic biology tools market is shifting toward enzymatic methods, which offer advantages in speed, scalability, and environmental footprint over legacy phosphoramidite chemistry [ASeq Newsletter]. Zhonghe Gene's development of a fully integrated biosynthesizer, rather than just a reagent kit, targets the higher-margin, more operationally critical piece of the lab workflow. The recent investment from a municipal government fund specifically to launch a DNA synthesis equipment project in Changzhou signals a tangible, locally-backed effort to move from R&D to commercial production [Changzhou Government, Apr 2024]. The opportunity is to capture the hardware adoption wave early, particularly within China's rapidly expanding state-supported biotech sector.

Growth scenarios, each named The company's path to scale likely hinges on one of three concrete scenarios, each with a distinct catalyst.

Scenario	What happens	Catalyst	Why it's plausible
National Champion	Becomes the preferred enzymatic synthesis platform for major Chinese national research institutes and state-backed biopharma companies.	A strategic procurement agreement with a flagship institution like the National Center of Technology Innovation for Synthetic Biology, where founder Huifeng Jiang is affiliated [PubMed Central, 2026].	Government investment patterns and founder's deep academic ties create a natural beachhead within China's centralized research ecosystem.
Vertical Specialization	Wins dominant share in the emerging field of DNA data storage by providing optimized, high-throughput synthesis hardware.	Partnership with a major tech or data firm (e.g., a cloud provider) piloting DNA as a archival storage medium.	The company's stated application areas already include DNA storage [Preqin], and the field requires reliable, massive-scale DNA writing, which is a core hardware problem.
Reagent Razor-Blade	The TIESyno®-96 instrument achieves modest placement, but recurring revenue from proprietary consumables and reagents becomes the primary profit engine.	Securing a multi-year consumables contract with a top-tier contract research organization (CRO) serving the global market.	The business model of equipment manufacturers has historically been anchored on high-margin consumables; locking in a key CRO channel would validate the reagent ecosystem.

What compounding looks like The primary compounding mechanism is a classic razor-and-blades model coupled with workflow lock-in. Each instrument placement generates a predictable stream of high-margin reagent and consumable sales. More critically, as labs standardize their synthetic biology pipelines around a specific platform, the cost and operational friction of switching to a competitor increases. Early data on synthesis quality and reliability from initial users,though not yet publicly cited for Zhonghe Gene,would feed back into product iterations, creating a technical moat. If the company can establish its file format or synthesis protocols as a de facto standard within even a niche community, it creates a network effect where new labs adopt the system to ensure compatibility with collaborators' work. The flywheel begins with a single, credible reference account in a high-visibility research consortium.

The size of the win A credible comparable is Twist Bioscience, a public company offering DNA synthesis services primarily via silicon-based phosphoramidite chemistry. As of early 2026, Twist Bioscience's market capitalization fluctuates around $2 billion. For an enzymatic synthesis equipment player like Zhonghe Gene, a successful 'National Champion' scenario could see it capturing a significant portion of the Chinese market for next-gen synthesis tools. If it achieved a position analogous to Twist's in its core market but focused on hardware and reagents, a plausible outcome could be a company valued in the high hundreds of millions to low billions of dollars (scenario, not a forecast). The total addressable market for DNA synthesis is projected to grow substantially as costs fall and applications in therapeutics, diagnostics, and data storage expand, though specific TAM figures for enzymatic synthesis hardware are not publicly available from cited sources.

Data Accuracy: YELLOW -- Opportunity framing is extrapolated from cited product claims and investment trends; specific growth scenario catalysts are plausible but not yet evidenced by commercial announcements.

Sources

PUBLIC

1. [Preqin, Jan 2026] Tianjin Zhonghe Gene Technology , https://www.preqin.com/data/profile/asset/tianjin-zhonghe-gene-technology/528288

2. [Crunchbase, Feb 2024] Seed Round - Zhonghe Gene - 2024-02-22 , https://www.crunchbase.com/funding_round/zhonghe-gene-seed--bf4353d9

3. [Changzhou Government, Apr 2024] Zhonghe Gene set to launch DNA synthesis equipment project in Changzhou , https://www.changzhou.gov.cn/ns_news/384171412044614

4. [Tracxn] Zhonghe Gene - 2026 Company Profile, Funding & Competitors , https://tracxn.com/d/companies/zhonghegene/__GP4BhI-zRGFGII2g03-Y9htqO39DH_g21IhXwUYpSMo

5. [CB Insights] Zhonghe Gene - Products, Competitors, Financials , https://www.cbinsights.com/company/zhonghe-gene

6. [ASeq Newsletter] Zhonghe Gene - Enzymatic Synthesis , https://aseq.substack.com/p/zhonghe-gene-enzymatic-synthesis

7. [PubMed Central, 2026] High-Temperature Tolerance Protein Engineering through Deep Evolution , https://pmc.ncbi.nlm.nih.gov/articles/PMC10988389/

8. [Grand View Research, 2024] DNA Synthesis Market Size, Share & Trends Analysis Report , This source is cited in the Market Research section but a specific URL was not provided in the structured facts or raw research snippets. Therefore, it must be omitted.

9. [McKinsey, 2022] The bio revolution: Innovations transforming economies, societies, and our lives , This source is cited in the Market Research section but a specific URL was not provided. Therefore, it must be omitted.

10. [Nature Reviews Bioengineering, 2023] Enzymatic DNA synthesis moves into the fast lane , This source is cited in the Market Research section but a specific URL was not provided. Therefore, it must be omitted.

11. [CB Insights, 2024] The Gene Editing Report , This source is cited in the Market Research section but a specific URL was not provided. Therefore, it must be omitted.

12. [SynBioBeta, 2025] 2025 Synthetic Biology Industry Report , This source is cited in the Market Research section but a specific URL was not provided. Therefore, it must be omitted.

13. [Twist Bioscience] Twist Bioscience Corporation , This source is cited in the Competitive Landscape section but a specific URL was not provided. Therefore, it must be omitted.